Mitomycin gel (Jelmyto), which received FDA approval in April 2020, addresses a need for a better way to treat low-grade UTUC, a malignancy that is challenging to manage. Tumor-ablative chemotherapy ...
Mitomycin C (MMC) is a quinone-containing antitumour antibiotic that is reductively activated by a variety of enzymatic systems to metabolites that alkylate and crosslink DNA (Dorr, 1988). The ...
Two pre-TURBT 40-mg intravesical mitomycin-C instillations significantly improved long-term recurrence outcomes versus TURBT ...
Single-agent therapy with Docetaxel or Pemetrexed is the current therapy of choice for second-line treatment in advanced non-small-cell lung cancer (NSCLC). The role of older agents was underattended ...
Adults with suspected bladder cancer are offered a single dose of intravesical mitomycin C, given at the same time as the first transurethral resection of bladder tumour (TURBT). A single dose of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results